A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 7,300 shares of IDYA stock, worth $274,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7,300
Previous 3,600 102.78%
Holding current value
$274,188
Previous $128,000 150.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$34.2 - $47.13 $7.25 Million - $9.98 Million
-211,847 Reduced 12.89%
1,431,446 $62.8 Million
Q4 2023

Feb 14, 2024

BUY
$24.59 - $35.83 $22.1 Million - $32.2 Million
898,193 Added 120.55%
1,643,293 $58.5 Million
Q3 2023

Nov 14, 2023

SELL
$21.07 - $29.77 $8.6 Million - $12.2 Million
-408,329 Reduced 35.4%
745,100 $20.1 Million
Q2 2023

Aug 14, 2023

BUY
$13.33 - $25.53 $1.9 Million - $3.63 Million
142,313 Added 14.07%
1,153,429 $27.1 Million
Q1 2023

May 15, 2023

BUY
$13.49 - $18.72 $1.68 Million - $2.33 Million
124,257 Added 14.01%
1,011,116 $13.9 Million
Q4 2022

Feb 14, 2023

SELL
$14.47 - $18.17 $5.32 Million - $6.68 Million
-367,829 Reduced 29.32%
886,859 $16.1 Million
Q3 2022

Nov 14, 2022

BUY
$9.24 - $15.79 $4.93 Million - $8.43 Million
533,644 Added 74.01%
1,254,688 $18.7 Million
Q2 2022

Aug 15, 2022

BUY
$8.28 - $13.88 $2.98 Million - $5 Million
360,452 Added 99.96%
721,044 $9.95 Million
Q1 2022

May 16, 2022

BUY
$11.18 - $24.02 $4.03 Million - $8.66 Million
360,592 New
360,592 $4.04 Million
Q1 2021

May 17, 2021

SELL
$13.48 - $23.77 $381,969 - $673,546
-28,336 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$12.17 - $17.52 $344,849 - $496,446
28,336 New
28,336 $397,000
Q3 2020

Nov 16, 2020

SELL
$11.22 - $14.46 $2.78 Million - $3.59 Million
-248,005 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$3.59 - $18.57 $890,337 - $4.61 Million
248,005 New
248,005 $3.52 Million

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.81B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.